Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair

Chest

Volumn 128, Issue 4, 2005, Pages 2563-2570

  Norozi, Kambiz ^a   Buchhorn, Reiner ^b   Kaiser, Christian ^b   Hess, Georg ^c   Grunewald, Rolf W ^b   Binder, Lutz ^b   Wessel, Armin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Cardiopulmonary exercise test; Congenital heart disease; Natriuretic peptides; Right ventricular dysfunction; Tetralogy of Fallot

Indexed keywords

ADRENALIN; ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; ENDOTHELIN 1; NORADRENALIN; RENIN;

ADULT; ARTICLE; BICYCLE ERGOMETRY; BLOOD SAMPLING; CARDIOVASCULAR SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; FALLOT TETRALOGY; FEMALE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HORMONE DETERMINATION; HUMAN; MALE; OXYGEN CONSUMPTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 27144516351     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2563     Document Type: Article

References (38)

1. Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med 1993; 329:593-599
2. Nollert G, Fischlein T, Bouterwek S, et al. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol 1997; 30:1374-1383
3. Oechslin EN, Harrison DA, Harris L, et al. Reoperation in adults with repair of tetralogy of Fallot: indications and outcomes. J Thorac Cardiovasc Surg 1999; 118:245-251
4. Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomie nervous activities in patients with congenital heart disease. Circulation 2003; 108:2368-2376
5. Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001; 51:489-494
6. Maisel AM. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure; what's next? Circulation 2002; 105:2328-2331
7. Maisel AM, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167
8. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135:825-832
9. Luchner A, Hengstenberg C, Löwel H, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002; 39:99-104
10. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107-115
11. Bolger A, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106:92-99
12. de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43:1584-1589
13. McNairy, Gardetto N, Clopton P, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2002; 143:406-411
14. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J 1999; 20:1799-1807
15. Pothoff G, Winter U, Wassermann K, et al. Ergospirometrische Normalkollektivuntersucliungen für ein Unsteady-state-Stufentestprogramm. Z Kardiol 1944; 83:116-123
16. Luchner A, Burnett JC, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in population. J Hypertens 2000; 18:1121-1128
17. Loke I, Squire IB, Davies JE, et al. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5:599-606
18. Hokanson JS, Moller JH. Adults with tetralogy of Fallot: long-term follow-up. Cardiol Rev 1999; 7:149-155
19. Jonsson H, Ivert T. Survival and clinical results up to 26 years after repair of tetralogy of Fallot. Scand J Thorac Cardiovasc Surg 1995; 29:43-51
20. Miyamura H, Eguchi S, Asano K. Long-term results of the intracardiac repair of tetralogy of Fallot: a follow-up study conducted over more than 20 years on 100 consecutive operative survivors. Surg Today 1993; 23:1049-1052
21. Norgaard MA, Lauridsen P, Helwind M, et al. Twenty- to thirty-seven-year follow-up after repair for tetralogy of Fallot. Eur J Cardiothorac Surg 1999; 16:125-130
22. Tulevski II, Dodge-Khatami A, Groenink M, et al. Right ventricular function in congenital cardiac disease: noninvasive quantitative parameters for clinical follow-up. Cardiol Young 2003; 13:397-403
23. Tulevski II, Groenink M, van der Wall EE, et al. Increased brain and atrial natriuretic peptides in patients with right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86:27-30
24. Hayabuchi Y, Matsuoka S, Kuroda Y. Plasma concentration of atrial and brain natriuretic peptide and cyclic guanosine monophosphate in response to dobutamine infusion in patients with surgically repaired tetralogy of Fallot. Pediatr Cardiol 1999; 20:343-350
25. Niezen RA, Helbing WA, van der Wall EE, et al. Biventricular systolic function and mass studied with MR imaging in children with pulmonary regurgitation after repair for tetralogy of Fallot. Radiology 1996; 201:135-140
26. Kruger S, Graf J, Merx MW, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147:60-65
27. Jia B, Zhang S, Chen Z, et al. Plasma endothelin 1 concentrations in children with congenital heart defects. Minerva Pediatr 1998; 50:99-103
28. Fratz S, Geiger R, Kresse H, et al. Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg 2003; 126:1724-1729
29. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentration in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84:2280-2285
30. Bouzas B, Kilner PJ, Gatzoulis MA. Pulmonary regurgitation: not a benign lesion. Eur Heart J 2005; 26:433-439
31. Redington AN, Oldershaw PJ, Shinebourne EA, et al. A new technique for the assessment of pulmonary regurgitation and its application to the assessment of right ventricular function before and after repair of tetralogy of Fallot. Br Heart J 1988; 60:57-65
32. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 2001; 103:2489-2494
33. Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interaction in tetralogy of Fallot: QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 1995; 92:231-237
34. Isnard R, Pousset F, Chafirovaskaia O, et al. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 2003; 146:729-735
35. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106:416-422
36. Pesola GR. The use of B-type natriuretic peptide (BNP) to distinguish heart failure from lung disease in patients presenting with dyspnea to the emergency department. Acad Emerg Med 2003; 10:275-277
37. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278-1283
38. Norozi K, Alpers V, Arnhold JO, et al. Incidence and risk distribution of heart failure in grown up with congenital heart disease in the long-time follow up after cardiac surgery [abstract]. Circulation. 2004; 110:11-498